中国防痨杂志 ›› 2021, Vol. 43 ›› Issue (1): 91-95.doi: 10.3969/j.issn.1000-6621.2021.01.017
收稿日期:
2020-09-28
出版日期:
2021-01-10
发布日期:
2021-01-12
通信作者:
陈绍平
E-mail:chenshaoping836@163.com
基金资助:
LI Guo, PANG Xian-qiong, XU Hua, JING Ming-yan, FAN Pang-shuang, CHEN Shao-ping()
Received:
2020-09-28
Online:
2021-01-10
Published:
2021-01-12
Contact:
CHEN Shao-ping
E-mail:chenshaoping836@163.com
摘要:
潜伏性结核感染(latent tuberculosis infection,LTBI)是一种对结核分枝杆菌抗原刺激产生持续免疫反应的状态,因其有进展为活动性结核病的风险,在世界范围内越来越受到重视。LTBI的筛查和预防性治疗是结核病综合防控工作的重要组成部分,但目前尚无LTBI的直接诊断方法和统一的治疗方案。除结核菌素皮肤试验和γ-干扰素释放试验两种常规检测方法外,我国新研发的重组结核杆菌融合蛋白(EC)[该制品名称是国家药典委员会确定的药品中文通用名称,“EC”为重组融合蛋白“结核分枝杆菌早期分泌性抗原靶6(ESAT-6)和培养滤液蛋白10(CFP-10)”]也可用于检测LTBI。异烟肼单药预防性治疗是目前应用最为广泛的方案,但含利福霉素的治疗方案因疗程较短,依从性较高,优势更明显。现阶段我国在LTBI领域的研究相对较少,预防性治疗覆盖率低,应积极开展LTBI相关研究,探索符合国情的预防性治疗方案。
李果, 庞先琼, 徐华, 敬明燕, 范庞双, 陈绍平. 潜伏性结核感染诊治进展[J]. 中国防痨杂志, 2021, 43(1): 91-95. doi: 10.3969/j.issn.1000-6621.2021.01.017
LI Guo, PANG Xian-qiong, XU Hua, JING Ming-yan, FAN Pang-shuang, CHEN Shao-ping. Progress in diagnosis and treatment of latent tuberculosis infection[J]. Chinese Journal of Antituberculosis, 2021, 43(1): 91-95. doi: 10.3969/j.issn.1000-6621.2021.01.017
[1] | World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020. |
[2] |
Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med, 2016,13(10):e1002152. doi: 10.1371/journal.pmed.1002152.
doi: 10.1371/journal.pmed.1002152 URL pmid: 27780211 |
[3] |
Gao L, Lu W, Bai L, et al. Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis, 2015,15(3):310-319. doi: 10.1016/S1473-3099(14)71085-0.
doi: 10.1016/S1473-3099(14)71085-0 URL pmid: 25681063 |
[4] | World Health Organization. WHO consolidated guidelines on tuberculosis module 1: prevention: tuberculosis preventive treatment. Geneva: World Health Organization, 2020. |
[5] | 高磊, 金奇. 关口前移: 结核潜伏感染及其控制. 中国防痨杂志, 2018,40(8):791-795. doi: 10.3969/j.issn.1000-6621.2018.08.003. |
[6] | 任哲雯, 成君, 徐彩红, 等. 肺结核患者密切接触者潜伏性结核感染预防性治疗研究进展. 中国防痨杂志, 2019,41(9):1021-1024. doi: 10.3969/j.issn.1000-6621.2019.09.020. |
[7] |
Stagg HR, Zenner D, Harris RJ, et al. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med, 2014,161(6):419-428. doi: 10.7326/M14-1019.
doi: 10.7326/M14-1019 URL |
[8] | 中华人民共和国国家卫生健康委员会. 中国结核病预防控制工作技术规范(2020年版). 国卫办疾控函〔2020〕279号. 2020-04-02. |
[9] | 中华人民共和国国家卫生和计划生育委员会. WS 196—2017结核病分类. 2017-11-09. |
[10] |
Zellweger JP, Sotgiu G, Corradi M, et al. The diagnosis of latent tuberculosis infection (LTBI): currently available tests, future developments, and perspectives to eliminate tuberculosis (TB). Med Lav, 2020,111(3):170-183. doi: 10.23749/mdl.v111i3.9983.
doi: 10.23749/mdl.v111i3.9983 URL pmid: 32624559 |
[11] | 蒋明娟, 刘思静, 汪川. 潜伏性结核感染诊断抗原研究进展. 现代预防医学, 2017,44(20):3837-3840. doi: CNKI:SUN:XDYF.0.2017-20-047. |
[12] | 中华医学会结核病学分会儿童结核病专业委员会, 国家儿童医学中心, 首都医科大学附属北京儿童医院, 等. 儿童结核分枝杆菌潜伏感染筛查和预防性治疗专家共识. 中华结核和呼吸杂志, 2020,43(4):345-349. doi: 10.3760/cma.j.cn112147-20200106-00006. |
[13] | 上海市防痨协会, 中国防痨协会青年理事会, 《中国防痨杂志》编辑委员会. 学校结核病疫情流行病学调查和现场处置专家共识. 中国防痨杂志, 2019,41(1):9-13. doi: 10.3969/j.issn.1000-6621.2019.01.004. |
[14] |
Tissot F, Zanetti G, Francioli P, et al. Influence of bacille Calmette-Guerin vaccination on size of tuberculin skin test reaction: to what size? Clin Infect Dis, 2005,40(2):211-217. doi: 10.1086/426434.
doi: 10.1086/426434 URL pmid: 15655737 |
[15] | 裴宁, 卢水华. WHO《潜伏性结核感染管理指南》要点解析及我国研究现状. 中国防痨杂志, 2015,37(7):736-739. doi: 10.3969/j.issn.1000-6621.2015.07.005. |
[16] |
Mulder C, Erkens C, Kouw P, et al. Tuberculin skin test reaction depends on type of purified protein derivative: implications for cut-off values. Int J Tuberc Lung Dis, 2019,23(12):1327-1334. doi: 10.5588/ijtld.18.0838.
doi: 10.5588/ijtld.18.0838 URL pmid: 31931917 |
[17] | 卢鹏, 成君, 路希维, 等. 科学开展预防性治疗加速遏制结核病进程. 中国防痨杂志, 2020,42(4):316-321. doi: 10.3969/j.issn.1000-6621.2020.04.004. |
[18] |
van Zyl-Smit RN, Pai M, Peprah K, et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med, 2009,180(1):49-58. doi: 10.1164/rccm.200811-1704OC.
doi: 10.1164/rccm.200811-1704OC URL pmid: 19342414 |
[19] |
Kahwati LC, Feltner C, Halpern M, et al. Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA, 2016,316(9):970-983. doi: 10.1001/jama.2016.10357.
doi: 10.1001/jama.2016.10357 URL pmid: 27599332 |
[20] |
Sun L, Xiao J, Miao Q, et al. Interferon gamma release assay in diagnosis of pediatric tuberculosis: a meta-analysis. FEMS Immunol Med Microbiol, 2011,63(2):165-173. doi: 10.1111/j.1574-695X.2011.00838.x.
doi: 10.1111/j.1574-695X.2011.00838.x URL pmid: 22077219 |
[21] |
Gao L, Li X, Liu J, et al. Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural China: follow-up results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis, 2017,17(10):1053-1061. doi: 10.1016/S1473-3099(17)30402-4.
doi: 10.1016/S1473-3099(17)30402-4 URL pmid: 28716677 |
[22] |
Li H, Xin H, Qian S, et al. Testing of tuberculosis infection among Chinese adolescents born after terminating the Bacillus Calmette-Guérin booster vaccination: subgroup analysis of a population-based cross-sectional study. Front Med, 2017,11(4):528-535. doi: 10.1007/s11684-017-0573-0.
doi: 10.1007/s11684-017-0573-0 URL pmid: 29101754 |
[23] |
Abubakar I, Lalvani A, Southern J, et al. Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study. Health Technol Assess, 2018,22(56):1-96. doi: 10.3310/hta22560.
doi: 10.3310/hta22560 URL pmid: 30334521 |
[24] | 高磊, 权竹声, 成君, 等. 结核分枝杆菌感染检测两步法在学校结核病控制工作中的应用探讨. 中华预防医学杂志, 2020,54(4):385-391. doi: 10.3760/cma.j.cn112150-20191204-00909. |
[25] | 中国防痨协会, 中国防痨协会学校与儿童结核病防治专业分会, 《中国防痨杂志》编辑委员会. 重组结核杆菌融合蛋白(EC)临床应用专家共识. 中国防痨杂志, 2020,42(8):761-768. doi: 10.3969/j.issn.1000-6621.2020.08.001. |
[26] |
Li F, Xu M, Qin C, et al. Recombinant fusion ESAT6-CFP10 immunogen as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, two-centre phase 2a clinical trial. Clin Microbiol Infect, 2016, 22(10): 889.e9-889.e16. doi: 10.1016/j.cmi.2016.07.015.
doi: 10.1016/j.cmi.2016.07.015 URL |
[27] | 李果. 2020年WHO综合指南更新解读: 结核预防性治疗. 医师在线, 2020,10(15):22-23. |
[28] |
Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med, 2011,365(1):11-20. doi: 10.1056/NEJMoa1005136.
doi: 10.1056/NEJMoa1005136 URL pmid: 21732833 |
[29] | Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev, 2010, 2010 (1): CD000171. doi: 10.1002/14651858.CD000171.pub3. |
[30] |
Golub JE, Cohn S, Saraceni V, et al. Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. Clin Infect Dis, 2015,60(4):639-645. doi: 10.1093/cid/ciu849.
doi: 10.1093/cid/ciu849 URL pmid: 25365974 |
[31] | 程馨禾, 边赛男, 张峣, 等. 潜伏性结核分枝杆菌感染的预防性治疗. 中华实验和临床感染病杂志(电子版), 2016,10(2):129-135. doi: 10.3877/cma.j.issn.1674-1358.2016.02.001. |
[32] |
Zenner D, Beer N, Harris RJ, et al. Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis. Ann Intern Med, 2017,167(4):248-255. doi: 10.7326/M17-0609.
doi: 10.7326/M17-0609 URL pmid: 28761946 |
[33] |
Galli L, Lancella L, Tersigni C, et al. Pediatric Tuberculosis in Italian Children: Epidemiological and Clinical Data from the Italian Register of Pediatric Tuberculosis. Int J Mol Sci, 2016,17(6):960. doi: 10.3390/ijms17060960.
doi: 10.3390/ijms17060960 URL |
[34] | 魏建华, 黄兴玲, 郭涛. 264例潜伏性结核感染两联抗结核药物不良反应临床分析. 宁夏医学杂志, 2018,40(2):171-172. doi: 10.13621/j.1001-5949.2018.02.0171. |
[35] |
Sterling TR, Scott NA, Miro JM, et al. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS, 2016,30(10):1607-1615. doi: 10.1097/QAD.0000000000001098.
doi: 10.1097/QAD.0000000000001098 URL pmid: 27243774 |
[36] | 杨清銮, 阮巧玲, 张文宏. HIV感染人群潜伏性结核感染筛查与预防性治疗. 临床内科杂志, 2019,36(11):729-732. doi: 10.3969/j.issn.1001-9057.2019.11.004. |
[37] |
Sun HY, Huang YW, Huang WC, et al. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan. Tuberculosis (Edinb), 2018,111:121-126. doi: 10.1016/j.tube.2018.05.013.
doi: 10.1016/j.tube.2018.05.013 URL |
[38] | 任哲雯, 张国龙, 龚德华, 等. 结核潜伏感染者对12周预防性治疗方案的接受意愿研究. 中国防痨杂志, 2020,42(5):503-509. doi: 10.3969/j.issn.1000-6621.2020.05.016. |
[39] |
Gao L, Zhang H, Xin H, et al. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study. Eur Respir J, 2018,52(6):1801470. doi: 10.1183/13993003.01470-2018.
doi: 10.1183/13993003.01470-2018 URL pmid: 30361241 |
[40] |
Swindells S, Ramchandani R, Gupta A, et al. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med, 2019,380(11):1001-1011. doi: 10.1056/NEJMoa1806808.
doi: 10.1056/NEJMoa1806808 URL pmid: 30865794 |
[41] |
Menzies D, Adjobimey M, Ruslami R, et al. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N Engl J Med, 2018,379(5):440-453. doi: 10.1056/NEJMoa1714283.
doi: 10.1056/NEJMoa1714283 URL pmid: 30067931 |
[42] | 姚晶, 顾凯侃, 李智红, 等. 结核潜伏感染的研究现况概述. 结核与肺部疾病杂志, 2020,1(1):82-88. doi: 10.3969/j.issn.2096-8493.2020.01.017. |
[43] |
Cui X, Gao L, Cao B. Management of latent tuberculosis infection in China: Exploring solutions suitable for high-burden countries. Int J Infect Dis, 2020,92S:S37-S40. doi: 10.1016/j.ijid.2020.02.034.
doi: 10.1016/j.ijid.2020.02.034 URL pmid: 32114201 |
[1] | 崔晓敬, 魏栋, 王春雷, 曹彬. 分子生物学和液体培养方法提高综合医院结核病病原学诊断能力的价值[J]. 中国防痨杂志, 2021, 43(2): 143-146. |
[2] | 米洁, 薛勇, 白雪娟, 吴雪琼. 淋巴细胞亚群检测在结核病诊疗中的应用进展[J]. 中国防痨杂志, 2021, 43(2): 178-185. |
[3] | 李潜, 汪林宝, 罗佩嘉, 韦林, 刘玉钢, 任磊鹏, 丁超. 两种技术对结核性脓胸不同手术标本病原学及耐药性检测结果分析[J]. 中国防痨杂志, 2021, 43(1): 52-57. |
[4] | 中国防痨协会. 结核病领域研究进展(2020年度)[J]. 中国防痨杂志, 2021, 43(1): 6-11. |
[5] | 张开义, 吕正煊, 刘永莉, 张乐, 朱江春, 喻明丽. 脓肿分枝杆菌致患者多系统播散性感染一例的诊治过程分析[J]. 中国防痨杂志, 2021, 43(1): 66-71. |
[6] | 刘健雄, 杜雨华, 沈鸿程, 张广川, 吴桂锋, 赖铿, 雷宇, 李铁钢. 2008—2018年广州市结核病患者诊断延误影响因素分析[J]. 中国防痨杂志, 2021, 43(1): 80-86. |
[7] | 周林, 刘二勇, 孟庆琳, 陈明亭, 周新华, 高微微, 林明贵, 谢汝明. 《WS 288—2017 肺结核诊断》标准实施后肺结核诊断质量评估分析[J]. 中国防痨杂志, 2020, 42(9): 910-915. |
[8] | 刘二勇, 王前, 周林, 张国钦, 张修磊, 马永成, 杨枢敏, 王毳, 孟庆琳, 陈明亭, 林明贵, 屠德华. 我国部分地区病原学检测阴性肺结核诊断质量现状分析[J]. 中国防痨杂志, 2020, 42(9): 916-920. |
[9] | 王前, 周林, 刘二勇, 赵雁林, 李涛, 陈明亭, 杨丽佳, 王嘉. 我国县级结核病定点医疗机构结核病诊断能力现况调查研究[J]. 中国防痨杂志, 2020, 42(9): 926-930. |
[10] | 梁瑞云, 方伟军, 任会丽, 黎惠如, 张晖. 非结核分枝杆菌肺病并发与未并发糖尿病患者的CT征象研究[J]. 中国防痨杂志, 2020, 42(9): 962-967. |
[11] | 南海, 张芸, 杨新婷, 段鸿飞. GeneXpert MTB/RIF对骨关节结核诊断价值的Meta分析[J]. 中国防痨杂志, 2020, 42(9): 973-980. |
[12] | 陈玉妹, 罗兴雄, 陈成江, 苏萍, 王春雷. 海南省地市及县级结核病定点医院服务能力分析[J]. 中国防痨杂志, 2020, 42(9): 992-993. |
[13] | 中国防痨协会 中国防痨协会学校与儿童结核病防治专业分会 《中国防痨杂志》编辑委员会. 重组结核杆菌融合蛋白(EC)临床应用专家共识[J]. 中国防痨杂志, 2020, 42(8): 761-768. |
[14] | 赵爱华, 康万里, 王国治, 高正伦, 都伟欣, 卢锦标, 沈小兵, 苏城, 徐苗, 郑素华. 重组结核分枝杆菌11kDa蛋白鉴别潜伏性结核感染与卡介苗接种的研究[J]. 中国防痨杂志, 2020, 42(8): 821-825. |
[15] | 陈凤芳, 马俊, 黄劲, 尹洪云, 沙巍, 杨光红, 冯永红. 建立结核感染T淋巴细胞斑点试验阳性的纵隔淋巴结结核与Ⅰ/Ⅱ期结节病诊断模型初探[J]. 中国防痨杂志, 2020, 42(8): 832-837. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||